Beova Drug Interactions

Vibegron is suggested to be a substrate for CYP3A4 or P-glycoprotein (P-gp).
Tolterodine: Coadministration of 100 mg^note) of Vibegron and 4 mg of Tolterodine, a substrate of CYP2D6, to 12 healthy adults resulted in increases in C_max and AUC_0-24 of Vibegron by 1.03-fold and 1.08-fold, respectively, compared with when Vibegron was given alone. Meanwhile, C_max and AUC_0-24 of Tolterodine were increased by 1.12-fold and 1.08-fold, respectively, compared with when Tolterodine was given alone.
Ketoconazole: Coadministration of 100 mg^note) of Vibegron and 200 mg of Ketoconazole a strong CYP3A4/P-gp inhibitor, to 10 healthy adults resulted in increases in C_max and AUC_inf of Vibegron by 2.22-fold and 2.08-fold, respectively [see Precautions].
Diltiazem: Coadministration of 100 mg^note) of Vibegron and 240 mg of Diltiazem, a moderate CYP3A4/P-gp inhibitor, to 12 healthy adults resulted in increases in C_max and AUC_inf of Vibegron by 1.68-fold and 1.63-fold, respectively.
Digoxin: Coadministration of Vibegron increased digoxin C_max and AUC by 21% and 11%, respectively.
Note): Approved dose of this drug is 50 mg.